Trastuzumab Deruxtecan Plus Pertuzumab Reduce a Risk of Progression or Death in First-Line Treatment for HER2-positive Advanced or Metastatic Breast Cancer By Ogkologos - November 3, 2025 279 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Breast09 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Lung Cancer Trial of Osimertinib Draws Praise—and Some Criticism July 5, 2023 Rucaparib Approved as Maintenance Treatment for Some Recurrent Ovarian Cancers May 4, 2018 Study Says Educational Materials for Chemo Often Require Higher Reading Level... September 25, 2019 New Blood Test Can Screen For Over 50 Cancers June 7, 2021 Load more HOT NEWS Survival According Circulating Tumour DNA Status in the Study of Adjuvant... Cancerul în comunitatea mea: progresul îngrijirilor pentru cancer în România The power of partnership – the unique alliance taking on brain... Should CAR T Cells Be Used Earlier in People with Non-Hodgkin...
